NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
New Insights On Pre-Existing AAV5 Abs in Haemophilia B Gene Therapy
Wolfgang Miesbach; Robert Klamroth/LinkedIn
Oct 6, 2025, 03:48

New Insights On Pre-Existing AAV5 Abs in Haemophilia B Gene Therapy

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”Exited to share our new paper: New insights on pre-existing AAV5 antibodies in haemophilia B gene therapy!

First comprehensive longitudinal analysis of AAV5 NAb stability over 6+ months in haemophilia B patients (median 8 months of follow-up).

Unlike most gene therapy trials that exclude NAb+ patients, HOPE-B (etranacogene dezaparvovec) enrolled participants regardless of pre-existing AAV5 NAb titers.

Study Highlights:

– 67 adult males with moderate-to-severe haemophilia B followed over median 8 months (240 days)
– 47.8% had pre-existing AAV5 neutralizing antibodies (NAbs) at screening – median titer was 58
– Comprehensive analysis of both neutralizing antibodies (NAbs) and binding antibodies (IgG/IgM)

Clinical Insights:

  • AAV5 NAb titers remain stable over 6+ months – median intra-patient coefficient variation only 25%
  • Strong correlation between NAb and IgG binding antibodies (r=0.96) across multiple timepoints
  • Age association: NAb positivity more frequent in patients ≥50 years, particularly those with prior hepatitis B/C exposure

Seroconversion Patterns:

NAb- to NAb+ Seroconversion:
Very rare: Only ~5% of participants (2 out of 67) seroconverted from NAb- to NAb+ during the lead-in period.

One clear case showed seroconversion at 4 months with contemporaneous transient IgM increase, consistent with new AAV exposure

NAb+ to NAb- Seroreversion:
More common: Approximately 10% of participants seroreverted from NAb+ to NAb-.

All participants who seroreverted had NAb titers ≤25 at screening, close to assay detection limits

Clinical Implications:

– Screening flexibility: NAb testing can be done several months before planned gene therapy without concern for significant titer changes
– Patient selection confidence: Provides robust data supporting inclusion of NAb-positive patients in etranacogene dezaparvovec treatment

Remaining Challenges:
– Different cell types, reporter systems, and MOI ratios across laboratories
– Variable calculation methods for titer determination
– No human anti-AAV calibrators for absolute quantification

Congratulations to Robert Klamroth and co-authors and thank you to CSL for supporting this study.”

Read the full article here.

Article: Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study

Authors: Robert Klamroth, Michael Recht, Nigel S. Key, Wolfgang Miesbach, Steven W. Pipe, Radoslaw Kaczmarek, Douglass Drelich, Blanca Salazar, Sandra Le Quellec, Paul E. Monahan, Nicholas Galante, Paul van der Valk, Jacqueline Tarrant

New Insights On Pre-Existing AAV5 Abs in Haemophilia B Gene Therapy

Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.

AAV5 antibodies Blanca Salazar bleeding disorders Douglass Drelich Etranacogene Dezaparvovec HBV HCV Health Hematology Hemophilia Hemostasis Hemostasis Today HOPE B Jacqueline Tarrant Medicine Michael Recht Nicholas Galante Nigel S. Key Paul E. Monahan Paul van der Valk Radoslaw Kaczmarek Robert Klamroth Sandra Le Quellec Steven W. Pipe Wolfgang Miesbach
NewsFeed